Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Payoneer Global Inc (PAYO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Payoneer Global Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Payoneer Global Inc trades at $7.1 (market cap $2.40B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 16.6× Payoneer Global Inc's market cap, and Payoneer Global Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | PAYO | |
|---|---|---|
Market Cap | $39.89B | $2.40B |
Sector | Health | Technology |
52-Week High | $491.22 | $7.42 |
52-Week Low | $278.09 | $4.27 |
Enterprise Value | $38.15B | $2.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Payoneer Global (PAYO) trades at $7.10, up 0.14% with a $2.3B market cap, following Nuvei's $2.75B acquisition announcement. The stock shows bullish technical signals with strong moving averages, while fundamentals reveal solid revenue growth to $821M in 2025 and healthy gross margins of 79.4%. Recent earnings beat expectations in Q1 2026, though Q4 2025 missed. Analyst consensus is bullish with a $8.20 price target, but acquisition-related legal scrutiny creates uncertainty.
The acquisition by Nuvei at $7.40 per share provides a near-term floor, but potential undervaluation claims and regulatory approval pose risks. Long-term investors may see upside if the deal completes above current price, while volatility is expected during the process. Revenue stability and margin strength support fundamental value, but execution risks and competitive pressures remain key watchpoints.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Payoneer Global Inc
Payoneer Global Inc is the world's go-to partner for digital commerce, everywhere. The company started as a cross-border payments platform that empowers businesses, online sellers, and freelancers. The platform allows the users to get paid in multiple currencies, bill global clients, and sell on marketplaces worldwide.
Read more on PAYO →
